Search Results

You are looking at 241 - 250 of 2,910 items for :

  • Refine by Access: All x
Clear All
Full access

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea

-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using

Full access

Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

interventions to minimize distress and improve patient quality of life. AB2016-29. Treatment Outcomes in Patients With Metastatic Neuroendocrine Tumors: Retrospective Analysis of a Community Oncology Database Maxine D. Fisher, PhD a ; Sonia Pulgar, MPH b

Full access

BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils

Zhuoran Tang, Chunyu Li, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Qi Wang, and Caicun Zhou

characteristics. The risk score was determined using LASSO Cox regression analysis. Meanwhile, we named this risk score as “TANlncSig”. TANlncSig was able to distinguish between better and worse survival outcomes in various patient datasets independently of other

Full access

HSR23-120: Real-World Observations Show Beneficial Outcomes in Patients With NSCLC Treated With Pembrolizumab for More Than 2 Years

Lucio Gordan, Rushir Choksi, Daniel Petro, Melissa Johnson, Anupama Vasudevan, Sandy English, Marielle Fares, Heidi Gidley, Teena Sura, and Prateesh Varughese

at patient outcomes after >2 years of P treatment. The aim of this real-world study was to evaluate patient outcomes related to P use for >2 years in patients with stage IV NSCLC. Using the de-identified Precision Q database, authors evaluated

Full access

HSR21-050: Access to Gastroenterology and Internal Medicine Physicians is Associated With Improved Outcomes in Colorectal Cancer: A Nation-Wide Analysis

Udhayvir Singh Grewal, Subhash Chandra Garikipati, Parth Rajeshbhai Shah, Shiva Jashwanth Gaddam, Aakash Rajendra Sheth, and Ghanshyam Mudigonda

conducted the current analysis to study the impact of access to various specialties on the overall outcomes in CRC patients. Materials and Methods: The National Provider Identifier (NPI) database was interrogated to identify the number of gastroenterology

Full access

CLO23-057: The Influence of Operability Status on Outcomes in Patients With T4a Larynx Cancer: An Institutional Experience

Ashley Schlafstein, Subir Goyal, Ashley Aiken, Jill Remick, Nabil Saba, James Bates, Soumon Rudra, Mark McDonald, Azeem Kaka, and William Stokes

Purpose/Objective(s): Analyses of national care patterns and outcomes among patients with T4 laryngeal squamous cell carcinoma (L-SCC) have demonstrated a concomitant increase in the use of larynx preservation (LP) and a decrease in overall

Full access

HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

use in the real-world setting is scarce. Objective : To examine treatment patterns and outcomes among BRAF+ cutaneous melanoma patients treated with adjuvant IO or DT in the United States. Methods: This was a retrospective cohort study using

Full access

CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic

Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau

to the cancer center. Pembrolizumab ED has been evaluated through pharmacokinetic studies and simulated model-based analyses, however clinical data are lacking. The aim of this study is to evaluate real-world outcomes and safety of ED vs standard

Full access

HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng

and associated outcomes (time to treatment discontinuation [TTD] and treatment adherence) in selpercatinib-treated US patients. Methods: This retrospective cohort study used de-identified data from two administrative real-world claims databases

Full access

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Aida Bujosa, Consolación Moltó, Thomas J. Hwang, José Carlos Tapia, Kerstin N. Vokinger, Arnoud J. Templeton, Ignasi Gich, Agustí Barnadas, Eitan Amir, and Ariadna Tibau

Background The FDA defines clinical benefit as an improvement in either the duration or the quality of life (QoL). 1 FDA criteria allow cancer drugs to be approved based on surrogate measures that will reasonably predict definitive outcomes